Evidence map›Paper›PMID 40721649›Full record

ArticleLeukemia2025

Rare germline variant in NFATC4 associated with familial CLL.

Gilad Itchaki, Harrison Bai, Grace Tiao, Reina Improgo, Ben E Oppenheimer, Siddha Kasar, Bethany Tesar, Stacey M Fernandes, Nathalie Pochet, John-Hanson Machado and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Gilad Itchaki *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-9064-8139
Harrison Bai *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Grace TiaoCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Reina ImprogoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Ben E OppenheimerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Siddha KasarDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Bethany TesarDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Stacey M FernandesDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Nathalie PochetCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-1820-5656
John-Hanson MachadoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-0477-3476
Emily M ThrashDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-3423-0336
Arnold S FreedmanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Gad GetzCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-0936-0753
Jennifer R BrownDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Jennifer_Brown@dfci.harvard.edu.ORCID http://orcid.org/0000-0003-2040-4961

Funding

Genetic Predisposition to Chronic Lymphocytic Leukemia (CLL)R01CA258924 · NCI · DANA-FARBER CANCER INST · PI BROWN, JENNIFER R · 2021 to 2025
$3.1M
Massachusetts General Hospital (MGH) Paul C. Zamecnik Chair in OncologyU.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA258924
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40721649

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.